The NEUF study: Treatment of r/r Philadelphia chromosome-positive ALL with blinatumomab

CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer

Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma

ASPEN: Results of a phase III randomised trial of zanubrutinib vs ibrutinib for patients with Waldenström macroglobulinemia

Background of the KEYLYNK-007 trial for advanced solid tumours

US MM-6: Long-term proteasome inhibition in multiple myeloma following an in-class transition from bortezomib to ixazomib

Investigating KRd versus KTd in NDMM patients with high-risk cytogenetics

VIALE-A: Venetoclax with or without in treatment-naïve patients with acute myeloid leukaemia

OPTIC: A dose-ranging study of 3 starting doses of ponatinib for chronic-phase chronic myeloid leukaemia

CANDOR updated results: KdD versus Kd in patients with RRMM according to prior lines of therapy

CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory multiple myeloma

GMMG-CONCEPT: Isa-KRd in front-line treatment of high-risk myeloma